Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | PNP | P00491 | 2/20 | 0.42 |
| ▸ | ACP1 | P24666 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7486955 | 1.00 | PKM (0.56) | PKMTSHRGAAHPGDADORA2A | |
| Hydrochloric Acid SCHEMBL5746470 | 0.99 | PKM (0.55) | PKMTSHRGAAHPGDADORA2A | |
| SCHEMBL9367365 | 0.85 | PKM (0.59) | PKMTSHRGAAHPGDADORA2A | |
| SCHEMBL14149475 | 0.85 | PKM (0.56) | PKMTSHRGAAHPGDADORA2A | |
| SCHEMBL14105392 | 0.82 | PKM (0.50) | PKMTSHRGAAHPGDADORA2A | |
| SCHEMBL1753177 | 0.78 | MAPK1 (0.55) | PKMTSHRGAAHPGDSMN1; SMN2 | |
| SCHEMBL14105606 | 0.74 | TSHR (0.47) | PKMTSHRGAAHPGDADORA2A | |
| SCHEMBL4923135 | 0.73 | HPGD (0.76) | TSHRHPGDSMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL11551662 | 0.73 | PKM (0.59) | PKMTSHRGAAADORA2API4KA | |
| SCHEMBL2808649 | 0.72 | PKM (1.00) | PKMTSHRGAAHPGDTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670809-B1 | SYNTHESIS AND MANUFACTURE OF PENTOSTATIN AND ITS PRECURSORS, ANALOGS AND DERIVATIVES | MAYNE PHARMA PLC (GB) | 2016-01-13 | — | — | EP | disclosed |
| US-7393954-B2 | Process for the production of pentostatin aglycone and pentostatin | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393954-B2 | Process for the production of pentostatin aglycone and pentostatin | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2008-07-01 | — | — | US | disclosed |
| US-20060241065-A1 | Ring-expanded nucleosides and nucleotides | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY | 2006-10-26 | — | — | US | disclosed |
| EP-1227103-B1 | Ring-expanded nucleosides and nucleotides | NABI (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20040077564-A1 | Ring expanded nucleosides and nucleotides | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY | 2004-04-22 | — | — | US | disclosed |
| US-6677310-B1 | ANTICARCINOGENIC AGENTS; BACTERICIDES, FUNGICIDES, PARASITICIDES; VIRICIDES AGAINST HEPATITIS, EPSTEIN-BARR, CYTOMEGALO AND HUMAN IMMUNODEFICIENCY VIRUS | NABI | 2004-01-13 | — | — | US | disclosed |
| EP-0724587-B8 | RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES | NABI (US) | 2003-01-29 | — | — | EP | disclosed |
| EP-0724587-B1 | RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES | NABI (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1227103-A2 | Ring-expanded nucleosides and nucleotides | Nabi (US) | 2002-07-31 | — | — | EP | disclosed |
| US-5843912-A | Ring-expanded nucleosides and nucleotides | UNIVERSY OF MARYLAND (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0724587-A4 | RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES | BURNS BARRY (US) | 1996-12-27 | — | — | EP | disclosed |
| EP-0724587-A1 | RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES | Burns, Barry (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995009175-A1 | RING-EXPANDED NUCLEOSIDES AND NUCLEOTIDES | BURNS BARRY (US) | 1995-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241065-A1 | Ring-expanded nucleosides and nucleotides | PNP, UMPS, ADA | PKM 1934/4885TSHR 4282/4885GAA 767/4885 |
| US-20040077564-A1 | Ring expanded nucleosides and nucleotides | PNP, PAICS, UMPS | PKM 1829/4885TSHR 4160/4885GAA 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.